Medications

Compounded semaglutide and nutrition: what to know

Compounded GLP-1 formulations are not equivalent to FDA-approved branded medications. This article addresses the nutritional considerations for patients who are using compounded semaglutide, with explicit clinical caveats.

This article addresses the nutritional considerations that may apply to patients using compounded semaglutide. Several points need to be stated explicitly before any nutritional content is useful.

Why “compounded semaglutide” became common

During the 2022-2024 supply-shortage period for FDA-approved semaglutide products, the FDA’s compounding regulations permitted certain pharmacies to compound semaglutide for individual patients. The supply-shortage status has changed; the regulatory landscape continues to evolve. Patients should consult current FDA communications and their prescribing clinician for the current status.

Many patients began GLP-1 receptor agonist therapy on compounded semaglutide and have continued on it; many others have transitioned to FDA-approved formulations. The patient population using compounded semaglutide remains substantial.

Nutritional considerations for compounded semaglutide

If the active ingredient in a compounded formulation is in fact semaglutide and is delivered at a comparable dose to an FDA-approved formulation, the nutritional considerations should in principle parallel those discussed in the Ozempic and Wegovy nutrition guide: protein adequacy, side-effect-driven undereating, hydration, and micronutrient sufficiency under reduced caloric intake.

The substantial caveat is that compounded formulations are not subject to the same manufacturing oversight as FDA-approved products. Active ingredient identity, purity, dose accuracy, and inactive-ingredient profile may all vary between compounding pharmacies. The nutritional framework that applies depends on what is actually being delivered, which is not always knowable from the patient’s side.

Side effects and compounded products

The published side-effect profile of FDA-approved semaglutide (nausea, vomiting, constipation, diarrhea, and the more serious effects identified in clinical trials) is the only formal evidence base. Patients on compounded products who experience side effects beyond the typical GLP-1 pattern, or symptoms that are unusual or alarming, should report those promptly to their prescribing clinician. The compounded formulation itself may be a relevant variable.

Practical nutritional points specific to compounded use

• Document your dose precisely. Compounded products are sometimes dosed in concentration units rather than the milligram doses used in FDA-approved formulations. Knowing your effective dose in milligrams (and, ideally, having that confirmed by your clinician) matters for any clinical conversation about side effects, response, or transitioning to an approved formulation.
• Maintain laboratory monitoring. Routine laboratory follow-up at clinician-defined intervals (commonly including a metabolic panel, lipid panel, HbA1c if relevant, and consideration of micronutrient labs) is the same standard whether the GLP-1 medication is FDA-approved or compounded.
• Be cautious about “supercharged” formulations. Some compounded products are marketed as containing additional ingredients (B12, lipotropic agents, peptides). These additions are not FDA-evaluated for safety or efficacy in this context and may interact with the patient’s other medications or comorbidities. Discuss with your clinician.

Transition planning

Patients considering a transition from compounded to FDA-approved semaglutide (or to tirzepatide / Zepbound) should plan that transition with their clinician. Specific considerations:

• The starting dose on the FDA-approved formulation is typically the standard initiation dose (e.g., Wegovy starting at 0.25 mg weekly), not the patient’s effective dose on compounded therapy. Re-titration is the norm.
• Side effects may transiently worsen during the transition phase as the dose-response and pharmacokinetic profile of the FDA-approved product establishes.
• Insurance coverage is a substantial practical question; the clinician’s office can typically advise on prior authorization processes.

Editorial position

GLP-1 Nutrition does not equate compounded semaglutide with FDA-approved Ozempic, Wegovy, or Rybelsus, and does not recommend either initiation or continuation of compounded GLP-1 therapy as a default. This article exists because patients on compounded semaglutide are part of the audience served by this site, and the nutritional considerations are real for them. The clinical decisions are not nutritional decisions; they are decisions for the patient and their prescribing clinician.

References

1. U.S. Food and Drug Administration. Medications containing semaglutide marketed for type 2 diabetes or weight loss. FDA Drug Safety Communication. (Most recent FDA communication on this topic should be consulted directly.)
2. American Society of Health-System Pharmacists. ASHP Guidelines on Compounding Sterile Preparations. (Most recent edition.)
3. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384(11):989-1002.
4. American Diabetes Association. Standards of Care in Diabetes — 2025: Section 8, Obesity and weight management. Diabetes Care. 2025;48(Suppl 1):S145-S157.